中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

138 records (took 0.025 seconds)

    SPECIMEN ANALYSIS METHOD AND IMAGE PROCESSING METHOD
    12.
    发明申请
    SPECIMEN ANALYSIS METHOD AND IMAGE PROCESSING METHOD 有权

    公开(公告)号：US20220067938A1

    公开(公告)日：2022-03-03

    申请号：US17405843

    申请日：2021-08-18

    Applicant: SCREEN Holdings Co., Ltd. ,  Kyoto Prefectural Public University Corporation

    Inventor： Maki HIRAI ,  Hiroshi OGI ,  Shunta ISHIHARA ,  Takahiro TSUJIKAWA ,  Kyoko ITOH

    IPC: G06T7/00 ,  G06K9/20 ,  G06T7/30 ,  G06T7/187 ,  G01N15/14

    Abstract: An image processing using a plurality of specimen images obtained by successively applying a plurality of types of staining to a specimen to be evaluated and imaging the specimen after staining for at least two types of staining is performed. The image processing comprises: extracting an inner region corresponding to inward of a cell membrane of a single cell in the specimen based on at least one of the specimen images, specifying a cell region corresponding to an individual cell included in the specimen by expanding the inner region outwardly, and performing image cytometry for the cell region based on the specimen images. In analyzing a pathological specimen on a cell-by-cell basis, it is possible to deal with multiple immunostaining and specify the positions of individual cells and evaluate each cell separately even when a cell density in the specimen is high.

    COMBINED AGENT FOR CELL THERAPY OF CORNEAL ENDOTHELIAL CELL
    19.
    发明申请
    COMBINED AGENT FOR CELL THERAPY OF CORNEAL ENDOTHELIAL CELL 审中-公开
    组合细胞治疗角膜内皮细胞的药物

    公开(公告)号：US20160317528A1

    公开(公告)日：2016-11-03

    申请号：US15108355

    申请日：2013-12-27

    Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION ,  THE DOSHISHA ,  SENJU PHARMACEUTICAL CO., LTD.

    Inventor： Noriko KOIZUMI ,  Naoki OKUMURA ,  Shigeru KINOSHITA

    IPC: A61K31/4745 ,  A61K9/00 ,  A61K35/44 ,  A61K35/30

    CPC classification number: A61K31/4745 ,  A61K9/0048 ,  A61K35/30 ,  A61K35/44 ,  A61K45/06

    Abstract: The present invention provides an agent for treating or preventing a disease, a disorder or a condition of a corneal endothelium, said agent comprising a corneal endothelial cell and a myosin II-specific inhibitor. More specifically, the myosin II-specific inhibitor is blebbistatin. The disease, the disorder or the condition is typically a disorder associated with Fuchs endothelial corneal dystrophy or corneal endothelial dysfunction (bullous keratopathy). Also provided is a method for treating or preventing a corneal endothelial disease, said method comprising a step of administering an effective amount of a myosin II-specific inhibitor together with a corneal endothelial cell to a subject.

    Abstract translation: 本发明提供了用于治疗或预防角膜内皮的疾病，病症或病症的药剂，所述药物包含角膜内皮细胞和肌球蛋白II特异性抑制剂。 更具体地说，肌球蛋白II特异性抑制剂是blebbistatin。 疾病，病症或病症通常是与Fuchs内皮角膜营养不良或角膜内皮功能障碍（大疱性角膜病）相关的病症。 还提供了治疗或预防角膜内皮细胞疾病的方法，所述方法包括向受试者施用有效量的肌球蛋白II特异性抑制剂与角膜内皮细胞一起的步骤。

    CORNEAL ENDOTHELIAL CELL MARKER
    20.
    发明申请
    CORNEAL ENDOTHELIAL CELL MARKER 审中-公开
    角膜内皮细胞标记

    公开(公告)号：US20160266114A1

    公开(公告)日：2016-09-15

    申请号：US14908036

    申请日：2014-07-28

    Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION ,  THE DOSHISHA ,  SENJU PHARMACEUTICAL CO., LTD.

    Inventor： Noriko KOIZUMI ,  Naoki OKUMURA ,  Hiroatsu HIRANO ,  Shigeru KINOSHITA ,  Morio UENO

    IPC: G01N33/569 ,  A61K35/30

    CPC classification number: G01N33/56966 ,  A61K35/30 ,  C12N5/0621 ,  G01N2333/705 ,  G01N2333/70596

    Abstract: The purpose of the present invention is to provide a method of purification and preparation of cultured corneal endothelial cells, and in particular, to provide cell surface markers for use in corneal endothelial cells not including transformed cells. Provided are cell markers for distinguishing normal cells and transformed cells, in particular normal and transformed corneal endothelium cells. These cell markers relate to specific cell surface markers, for example, to a normal corneal endothelial surface marker such as CD166, and a transformed cell surface marker such as CD73. By using the transformed cell surface marker such as CD73 to remove transformed cells by sorting, it becomes possible to improve purity of a normal cultured corneal endothelium. By using normal corneal endothelial surface marker such as CD166, or by combined use with the transformed cell surface marker, it becomes possible to provide a means for verifying the purity of a prepared corneal endothelium.

    Abstract translation: 本发明的目的是提供一种纯化和制备角膜内皮细胞的方法，特别是提供用于不包括转化细胞的角膜内皮细胞的细胞表面标志物。 提供用于区分正常细胞和转化细胞的细胞标志物，特别是正常和转化的角膜内皮细胞。 这些细胞标志物涉及特定细胞表面标志物，例如与正常角膜内皮表面标志物如CD166和转化的细胞表面标志物如CD73相关。 通过使用转化的细胞表面标记如CD73通过分选来除去转化的细胞，可以提高正常培养的角膜内皮的纯度。 通过使用正常的角膜内皮表面标记如CD166，或通过与转化的细胞表面标记物的组合使用，可以提供一种验证制备的角膜内皮的纯度的方法。

Patent Agency Ranking